Evren Technologies, Inc

Advancing PTSD Treatment with an FDA Breakthrough Device

Claim My Business
Security Type
Common Stock
Technology, Healthcare & Medical
Min Investment
Gainesville, FL
Offering Date
March 25, 2022
Expected Close Date
August 29, 2022
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

Evren Technologies is developing a discrete earbud that utilizes a groundbreaking treatment for PTSD to help people easily manage their symptoms and improve outcomes. Backed by clinical evidence, the Phoenix® improves patient health and well-being with fewer side effects and higher patient engagement than seen with current prescription drugs and therapies.*


StartEngine OWNERS Exclusive Click here to learn more

$399+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

Friends and Family Early Birds
Invest within the first 72 hours and receive 15% bonus shares.





$1,000+ Investment
Investor | $1,000+ Invest $1,000+ and receive 50% off device purchase (coupon for use once the product is available on the market).

$5,000+ Investment
Watt | $5,000+ Invest $5,000+ and receive 5% bonus shares + 50% off device purchase (coupon for use once the product is available on the market).

$10,000+ Investment
Franklin | $10,000+ Invest $10,000+ and receive 10% bonus shares + 50% off 2 device purchases (coupons for use once the product is available on the market).

$25,000+ Investment
Edison | $25,000+ Invest $25,000+ and receive 20% bonus shares + 50% off 3 device purchases (coupons for use once the product is available on the market).

$50,000+ Investment
Tesla | $50,000+ Invest $50,000+ and receive 25% bonus shares + 50% off 4 device purchases (coupons for use once the product is available on the market).

Key Deal Facts

FDA Breakthrough Device Designation | Evren’s device, the Phoenix®, was recently awarded Breakthrough Device Designation by the FDA, demonstrating that it could provide better treatment than the current standard of care in the serious, life-threatening condition of PTSD. Evren is also the recipient of the SBIR Phase I award for a "Programmable tVNS research device for PTSD and related conditions."

Novel Technology for a Massive Growing Market | PTSD is an underserved, $22.5 Billion-dollar market with 66% of those suffering currently seeking new treatment solutions. 15 Million Americans will suffer from PTSD in any given year and over 60 million had PTSD during the height of the COVID shutdown.**

High User Satisfaction and Low Dropout Rates | 100% of Phoenix® users wanted to continue using the device after the pilot trial and all of them were willing to pay out-of-pocket for it.

Management Team / Advisory Board Bios

Neil Euliano

Chief Technology Officer

Neil Euliano has spent the past 20 years leading teams developing medical devices and technology. He is the chief designer and manager of the FDA cleared Philips Healthcare VentAssist team that developed intelligent decision support software for ventilated patients. He holds over 40 US patents and has ten more pending. In addition, he has a long history in managing multi-disciplinary medical development teams and 19 years of experience managing R&D grants, including over $12M in industry and government funded research. His commercialization and entrepreneurial experience includes being the cofounder of two companies, both of which led to FDA clearance, commercial sales, and acquisition. He has been involved in the successful FDA clearance of more than 6 medical devices. 
Euliano holds a PhD in Signal Processing and Electrical Engineering, an MSEE in Electrical Engineering, and a BSE in Computer Science all from the University of Florida.

Joshua Kelly

Associate Product Manager and Corporate Secretary

Josh Kelly started with the Company as an Associate Product Manager, but was appointed Corporate Secretary in December 2021. He previously was a consultant with Asymetric Solutions, and a Deptuy State Director - Wisconsin for In Field Strategies. He gratudated with a degree in public relations from the University of Florida.

Kimberly A Ramsey

Chief Financial Officer

A serial entrepreneur, with 30 years progressive corporate finance and operations experience Ramsey has played a key role in raising over $100 million, including several successful IPO’s. Most recently, she has been providing executive consulting services to medical device start-ups as founder and president of Bio/Med CXO. As co-founder and Chief Financial Officer for OBMedical Company, she played a key role in forwarding a ground-breaking wireless fetal/maternal monitor for use in labor and delivery departments, raising over $10M in private equity, leading to a successful acquisition by Philips Healthcare. Prior to that, she was key to successful mergers and IPOs in the biotech, med device and high-tech arenas. Ramsey holds a BSAc from the Fisher School of Accounting at the University of Florida. 

Stephanie Warrington

Member of the board of directors

Ms. Warrington has been an independent consultant since 2014, advising a wide range of early stage medtech and bgiotech companies. She was a founder, president and director of TrueMotion Spine, Inc., a Co-founder and VP, Corporate Development for Xhale, Inc., and President of Synogen, Inc. She holds an MBA, an MHA, and a BS in Business Administration from the University of Florida.

Robert V. House

Member of Board of Directors

Dr. House is an independent consultant and was previously Senior Vice President, Government Contracts of Ology Bioservices, with over 20 years' experience leading the contract management and oversight process of major US Government contracts with various agencies including the DoD, NIH, HHS, and other federal entities. He is also a director of Arrevus, Inc. He has more than 76 peer reviewed publications, plus numerous review articles, book chapters, and books. In addition, he is an adjunct professor at George Mason University. Dr. House is a graduate of the University of North Carolina at Chapel Hill, where he received his BA (Zoology), his MS in Public Health, and his PhD (Medical Parasitology). He will play a major role in our non-dilutive financing initiative. 

Richard Ferrari

Member of Board of Directors

Mr. Ferrari is a Co-Founder of De Novo Ventures which has $650 million under management and which is one of the premier firms dedicated to Medical Devices and Biotechnology. He has raised over a billion dollars for companies he has directly influenced and participated in approximately a 1.5 billion dollars in acquisition events. 
Additionally, he has been a successful CEO of two publicly traded medical technology companies. Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters which was eventually acquired for $125 million by Boston Scientific. His most recent success, CardioThoracic Systems (CTS), the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, was acquired by Guidant for $350 million in November 1999. Mr. Ferrari was a co-founder of CTS and the force that led the company to an initial public offering in only 7 months, the fastest of any medical technology company in history. Additionally, Rich was the co-founder of the MTG Group which developed Ensure femoral closure device which sold to J&J for $100 Mill returning 10x to investors and also IVS which developed the Star Close and sold to Abbott for $100Mill also returning 10x to investors. He is also the co-founder of Transaortic an integrated femoral sheath and embolic capture system for TAVR procedure which sold last year to Medtronic. He was also the Executive Chairman of SentreHeart where he led the acquisition to Atricure for $300Mill. 
Mr. Ferrari is the recipient of the Mallinckrodt Award for Excellence in Medicine and has been a finalist for the Entrepreneur of the Year Award. He holds a BS degree from Ashland University and an MBA from the University of South Florida.

Suha Jhaveri

Member of the Board of Directors

Ms. Jhaveri is presently the Chief Commercial Officer and Head of Business Development of Leyden Labs. Previously she was VP, Market Development of Vir Biotechnology, Global Commercial Leader and New Product Planning for Ultragenyx Pharmaceuticals. Prior to that, she was the Chief Operating Officer of OBMedical Company, and held a variety of executive positions with biotech and tech companies as well as working as a consultant for Boston Consulting Group. She holds an MBA from Harvard, a MA in Economic Development from the University of Sussex, and a BA in International Relations from Stanford University.

Marcus Elliot

VP of R&D

Vice President of R&D. Responsible for executing on the Company's overall technology vision & strategy, driving development execution, and bringing products to market on time and within budget.
Amount Raised : $217,929
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter